The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies

Abstract excerpt

Gene therapy is a promising therapeutic strategy for genetic and acquired hematologic diseases. With the improvements in gene transfer and expression, factors affecting safety and efficacy of gene therapy can now be evaluated to establish the best clinical benefit-to-risk ratio. The induction of immune responses against gene therapy components is one of the potential limitations. We studied the occurrence of such...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Immune Cell Function and Interaction
• Share to Polyomavirus and related diseases
• Share to Viral-associated cancers and disorders